Regulation of Tubulin Expression by Micro-RNAs: Implications for Drug Resistance - Methods in Cell Biology - page 72

FIGURE 5.5
Schema for paclitaxel treatment of MDA-MB-231 breast cancer cells and survival factors,
ZEB1 and

-tubulin isotype classes I, III, and IVB. Paclitaxel treatment increases
miR-200c activity. MiR-200c has a reciprocal relationship with the epithelial-to-mesenchymal
inducer ZEB1, and miR-200c also regulates

b

b -tubulin isotype classes I, III, and IVB

( Lobert et al., 2013 ). Thus, changes in these -tubulin isotypes are biomarkers for alterations

in cell phenotypes that indicate tumor progression.

b

References
Anonymous, American Cancer Society (2012). Chemotherapy for Breast Cancer. http://
www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-treating-chemotherapy ,
retrieved 4/21/2013.
Bartel, D. P. (2004). MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell , 116 ,
281-297.
Brown, S. (2013). RNA sequencing with NGS. In S. M. Brown, J. Goecks, & J. Taylor (Eds.),
Next-generation DNA sequencing informatics (pp. 171-186). New York: Cold Spring
Harbor Laboratory Press.
Burk, U., Schubert, J., Wellner, U., Schmalhofer, O., Vincan, E., Spaderna, S., et al. (2008). A
reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT
and invasion in cancer cells. EMBO Reports , 9 (6), 582-589.
Cabral, F. (2008). Mechanisms of resistance to drugs that interfere with microtubule assembly.
In T. Fojo (Ed.), The role of microtubules in cell biology, neurobiology and oncology
(pp. 337-356). New York, NY: Humana Press.
Cittelly, D. M., Dimitrova, O., Howe, E. N., Cochrane, D. R., Jean, A., Spoelstra, N. S., et al.
(2012). Restoration of miR-200c to ovarian cancer reduces tumor burden and increases
sensitivity to paclitaxel. Molecular Cancer Therapeutics , 11 (12), 2556-2565.
Cochrane, D. R., Spoelstra, N. S., Howe, E. N., Nordeen, S. K., & Richer, J. K. (2009).
MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting
chemotherapeutic agents. Molecular Cancer Therapeutics , 8 (5), 1055-1066.